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Abstract
Two recombinant Fasciola hepatica antigens, saposin-like protein-2 (recSAP2) and cathepsin L-1 (recCL1), were assessed
individually and in combination in enzyme-linked immunosorbent assays (ELISA) for the specific serodiagnosis of human
fasciolosis in areas of low endemicity as encountered in Central Europe. Antibody detection was conducted using ProteinA/
ProteinG (PAG) conjugated to alkaline phosphatase. Test characteristics as well as agreement with results from an ELISA
using excretory–secretory products (FhES) from adult stage liver flukes was assessed by receiver operator characteristic
(ROC) analysis, specificity, sensitivity, Youdens J and overall accuracy. Cross-reactivity was assessed using three different
groups of serum samples from healthy individuals (n = 20), patients with other parasitic infections (n = 87) and patients with
malignancies (n = 121). The best combined diagnostic results for recombinant antigens were obtained using the recSAP2-
ELISA (87% sensitivity, 99% specificity and 97% overall accuracy) employing the threshold (cut-off) to discriminate between
positive and negative reactions that maximized Youdens J. The findings showed that recSAP2-ELISA can be used for the
routine serodiagnosis of chronic fasciolosis in clinical laboratories; the use of the PAG-conjugate offers the opportunity to
employ, for example, rabbit hyperimmune serum for the standardization of positive controls.
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Introduction
In Central Europe, the most frequently encountered autoch-
thonous helminthic infections that require appropriate immuno-
diagnostic support include both forms of echinococcosis (Echino-
coccus multilocularis and Echinococcus granulosus), toxocarosis (Toxocara
spp.), trichinellosis (Trichinella spp.), ascariosis (Ascaris lumbricoides, A.
suum) and fasciolosis (Fasciola hepatica). Other helminthoses are
diseases encountered in the context of travel medicine and sojourn
in tropical or subtropical areas. Generally, the immunodiagnosis of
helminthic infections is challenged particularly by the problem of
high serological cross-reactivity when using crude or inadequately
purified antigens. Another serodiagnostic problem relates also to
cancer patients who raise antibodies against predominantly
carbohydrate epitopes that might be common to helminth
antigens [1,2,3], as exemplified e.g. by cross-reactive anti-P1
antibodies that can be elevated in some cancer patients as well as
in echinococcosis and fasciolosis patients [4,5].
Thus far, immunodiagnostic tools/methods for echinococcosis
[6,7], toxocarosis [8], trichinellosis [9] and ascarosis [10] that
achieve measures of specificity and sensitivity permissible for
routine use or commercialization have been developed. However,
the immunodiagnosis of fasciolosis, in Central European regions of
low endemicity, has remained a major challenge, and routine
diagnostic laboratories are struggling with the selection of a
suitable and reliable test. Nevertheless, recent improvements have
been published, mainly by Latin and North American groups on
the use of purified antigens, such as Fas2 [11], CL1 [12] or
FhSAP2 [13,14]. To date, these antigens have not yet been (i)
validated according to the standard/s required of routine
diagnostic laboratories operating under Central European in-
fectiological conditions and ISO 17025 norms, (ii) assessed in
relation to specificity (e.g., considering cancer patients) or (iii)
directly compared with each other for diagnostic performance.
Based on a review of the literature, we selected two promising
but different recombinant Fasciola antigens, the F. hepatica saposin-
like protein-2 antigen (SAP2) [15] and the cathepsin L1 cysteine
proteinase (CL1) [16] to establish and subsequently assess an
optimized ELISA for the serodiagnosis of human fasciolosis. In this
assessment, an emphasis was placed on the immunodiagnostic
discrimination from other (hepatic) parasitological problems
encountered in Central Europe, such as alveolar echinococcosis,
toxocarosis and ascariosis, but also other parasitic diseases
acquired during overseas travel. In addition, one of the most
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frequently encountered differential diagnostic problems in hepatic
and other organ disorders are tumors, which even upon use of
various imaging procedures, may not be readily discriminated
from particular parasitoses. Moreover, sera from cancer patients
are also known sometimes to cause serological cross-reactivity, as
has been documented, e.g. for echinococcosis serology
[1,2,3,17,18]. Therefore, one of the crucial considerations for
the present study was the inclusion of sera from 121 cancer
patients that had already been previously investigated for their
putative cross- or non-specific reactivity with Echinococcus antigens
[2,3].
The working hypothesis of the present study was that, if both
recombinant antigens exhibit a similarly high specificity, then their
direct combination might yield a higher diagnostic sensitivity than
when employed as single antigens. Therefore, we compared the
ELISAs using recSAP2, recCL1 and recSAP2 plus recCL1 with
the conventional ELISA (ISO-17025) using excretory-secretory
products from adult F. hepatica (Fh_E/S). In preliminary experi-
ments with the conventional FhES-ELISA, we had shown that a
conventionally used anti-huIgG-alkaline phosphatase conjugate
exhibited the same diagnostic performance as a ProteinA-
ProteinG-AP-conjugate [PAG-AP] (Gottstein et al., unpublished).
Based on these findings and the fact that for PAG-AP a positive
control serum of animal origin can be used, we elected to conduct
the present study using PAG-AP.
Materials and Methods
Ethics statement
All serum samples from humans were collected as part of public
health and clinical diagnostic activities, were available prior to the
commencement of this study and were treated anonymously,
Samples from blood donors were obtained under informed written
consent and provided by the Swiss Blood Transfusion Center
(SRK). This study was approved by the IPA Review Board of the
Vetsuisse Faculty of Bern, Switzerland.
Positive reference serum samples
Fasciolosis. From 30 sera from people with fasciolosis were
available for testing; 18 samples were from Swiss fasciolosis
patients that had been diagnosed in the context of an outbreak in
2009 [19], 5 sera were from patients that had entered routine
diagnostic investigations following requests by clinicians, in the
context of the routine diagnostic performances at the Institute of
Parasitology in Bern (cases matching criteria (ii) described below),
and 7 other sera were from Spanish fasciolosis patients infection
confirmed by coprological examination. Inclusion criteria were as
follows: (i) coprological detection of F. hepatica eggs by flotation,
using three temporally independent fecal samples per patient
(n = 17); or (ii): epidemiological (i.e. living temporally and spatially
in the outbreak area) and clinical evidence of fasciolosis (i.e.
elevated liver enzymes or cholangitis or cholestatic jaundice;
ultrasonographically revealed thickening of the gallbladder or
dilatation of the bile ducts; marked peripheral eosinophilia) and,
also simultaneously, positive F. hepatica serology in a FhES-
ahuIgG-AP-ELISA that had been validated for routine diagnosis
in our laboratory (ISO-17025) (n = 13).
Negative reference serum samples
Other parasitoses. Sera used for assessing test specificities
and cross-reactions due to other parasitic infections were obtained
from 87 persons with the following clinically, parasitologically
and/or histologically proven infections [numbers of patients
investigated]: hepatic alveolar echinococcosis (clinical P2/P4-N1-
M0 status) [n = 5]; hepatic cystic echinococcosis (clinical CE1 or
CE2 status) [n = 5]; infection with Schistosoma spp. [n = 8]; Taenia
solium neurocysticercosis [n = 7]; Strongyloides stercoralis infection
[n = 6]; Visceral larva migrans (Toxocara spp.) [n = 10]; Trichinella
spiralis infection [n = 8]; filariosis by Onchocerca volvulus [n = 6];
ascariosis (Ascaris spp.) [n = 10]; Entamoeba histolytica liver abscess
[n = 7]; visceral leishmaniasis (Leishmania infantum) [n = 7]; malaria
(Plasmodium falciparum) [n = 8]. All of these sera had been pre-
selected based on high antibody reactions against antigens of the
respective homologous parasite species as tested by ELISA and/or
IFAT.
Cancer patients. 121 adult patients (mean age 57613 years
of age) admitted to the outpatient clinic of the Institute of
Oncology, University Hospital of Bern, between 1995 and 1997,
who had donated serum for a previous, ethically approved study
on echinococcosis serology [2]. The sera were stored at 280uC
until inclusion into the present study. Inclusion criteria for the
patients had been: histologically confirmed malignancy, no history
or radiological finding suggestive of hepatic parasitoses, and ages
ranging between 18 and 85 years. The distribution of the different
malignancy types was as follows: neoplasm of the gastrointestinal
tract (20 cases), lymphoma (31 cases), breast cancer (19 cases), lung
cancer (14 cases), prostate/testicular cancer (8 cases), sarcoma (5
cases), leukemia (3 cases), nasopharyngeal neoplasm (2 cases),
histiocytosis (1 case), gynaecological neoplasm (5 cases), melanoma
(4 cases), myeloma (4 cases), bladder/kidney neoplasm (2 cases),
pancreatic neoplasm (1 case), neoplasm of the central nervous
system (CNS) (2 cases).
Negative control sera. The sera used for the determination
of normal ranges and parameters respective to the different
antigens were from 20 healthy Swiss blood donors, matched by
age and gender the group of the abovementioned fasciolosis
patients.
F. hepatica E/S-antigen
Excretory-secretory products (FhES) from F. hepatica were
prepared as described elsewhere [20]. Briefly, adult flukes were
collected from the bile ducts from sheep livers obtained from a
slaughterhouse and were washed several times in 0.01 mol/L
phosphate-buffered saline (PBS), pH 7.4 at room temperature.
The flukes were incubated under sterile conditions at 37uC for
24 h in serum-free RPMI-1640 medium supplemented with
25 mmol/L HEPES buffer, 7.5% sodium bicarbonate, containing
Author Summary
To improve the serodiagnosis of human fasciolosis caused
by Fasciola hepatica, we comparatively evaluated the
accuracy of two different enzyme-linked immunosorbent
assays (ELISAs) based on the use of two published
recombinant antigens. The best performance was
achieved with the recombinant F. hepatica saposin-like
protein-2 antigen (recSAP2). Although the F. hepatica E/S
antigen exhibited a slightly higher diagnostic sensitivity,
the higher specificity performance of recSAP2 renders this
antigen very suitable for application in low endemic areas,
especially when coupled to an easy and standardized
production facility as compared to the relatively complex
production procedure for an E/S antigen. Conclusively, the
recSAP2-ELISA can be used as a routine individual
serodiagnostic test for human fasciolosis, especially when
backed up by a compatible clinical history together with
other serodiagnostic technique for other helminth infec-
tions of the liver, e.g. alveolar or cystic echinococcosis.
recSAP2- and recCL1- in Human Fasciola-ELISA
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100 mL penicillin and 100 mg/mL streptomycin. The medium was
then sedimented (5,0006 g for 10 min at 4uC) to remove any
remaining particles. The supernatants were collected and then
concentrated using an YM-10 membrane filter system (Amicon
Corp., Lexington, MA). Protein concentrations were assessed with
a Bradford based protein assay (BioRad Laboratories, Cressier,
Switzerland).
F. hepatica recombinant saposin-like protein-2 antigen
(recSAP2)
A fresh, morphologically intact and viable adult F. hepatica was
isolated from an ovine bile duct and immediately put into RNA
later (Invitrogen) for storage. Using peqGold RNAPure and
peqGOLD OptiPure (both PeqLab), RNA was isolated according
to the manufacturer’s manual and by using a poly-T primer cDNA
was prepared with the Omniscript RT kit (Qiagen). The coding
sequence of the saposin-like protein-2 antigen (recSAP2) was
amplified by PCR (initial denaturation: 98uC - 3 min, amplifica-
tion: 25698uC–20 sec, 58uC–20 sec, 72uC–30 sec, and a final
72uC step for 5 min) using the primers FhSAP-forward (59-
CACCAACCCACTGTTCGTGTTAATG) and FhSAP-reverse
(59-CTAGCACAGCTTGATTAAACG). Primer FhSAP-dw con-
tained a N-terminal CACC stretch needed for the directional in-
frame cloning of the amplicon (306 bp) into the Champion pET
Directional Topo Expression Kit (Invitrogen). Insertion was
verified by sequencing, and clones containing a perfect matching
sequence were used for pilot experiments of expression. The clone
expressing the highest level of recSAP2 was then used for large
scale expression: 10 ml of overnight culture were diluted in 1 l
Luria Bertani (LB) medium containing 100 mg/ml ampicillin
(Sigma) and shaken at 37uC until the OD600 reached 0.5. The
protein expression was then induced by adding 1 mg IPTG. After
shaking for 3.5 h at 37uC, the cells were pelleted by sedimen-
tation (15 min, 4,0006g) and the recSAP2 was isolated under
denaturating conditions using 2 Protino Ni-IDA 1000 packed
columns (Machery-Nagel) according to the manufacturer’s
instructions, with the following exception. After washing, under
denaturating conditions, the columns were washed with 10 ml
non-denaturating buffer (50 mM NaH2PO4, 300 mM NaCl), and
the recombinant protein was eluted three times with 1 ml non-
denaturating elution buffer (50 mM NaH2PO4, 300 mM NaCl,
250 mM imidazole, pH 8.0). To reach ELISA-stage, the recSAP2
was precipitated with saturated ammonium sulfate solution, and
the precipitate dissolved in ELISA coating buffer (100 mM
sodium carbonate, pH 9.6). Storage prior to use for ELISA was
at 280uC.
The purity and antigenicity of the recSAP2 were assessed by
silver-staining of SDS-PAGE gels [21] and Western blot analyses,
as described previously for recP29, a recombinant antigen of E.
granulosus [22].
Recombinant cathepsin L-1 protein (recCL1) of F.
hepatica
The complete cDNA sequence encoding F. hepatica secreted
CL1 was retrieved from GenBank. Forward (59- GTACCCGA-
CAAAATTGACTGG-39) and reverse (59- TCACGGAAATC-
GTGCCACCAT-39) primers were designed to amplify the
appropriate region of the protein (220 amino acid), without the
C-terminal propeptide (55 amino acid). A CACC-tag was added to
the 59 end of the forward primer for further cloning into the
Champion pET Directional Expression kit (Invitrogen).
The cDNA encoding the CL1antigen (24.2 kDa) was amplified
by PCR of 250 ng of F. hepatica cDNA as a template (the same as
used to amplify recSAP2), 200 mM dNTPs, 0.5 mM of each
forward and reverse primer, in a total volume of 50 ml with 1 U of
Phusion High-Fidelity DNA polymerase (New England Biolabs).
The amplification was carried out using an initial denaturation of
98uC for 1 min, followed by 25 cycles of denaturation at 98uC for
30 s, annealing at 58uC for 30 s and an extension at 72uC for 30 s.
The final polymerization was carried out at 72uC for 5 min. The
658 bp PCR product was purified using High Pure PCR Product
Purification Kit (Roche) and then cloned into Champion pET
expression vector. Competent E. coli (TOP10) cells were
transformed using the manufacturer’s instructions (Invitrogen).
The transformed bacteria were incubated on LB plates containing
100 mg/ml of ampicillin at 37uC overnight, and colonies
containing the insert were identified by colony PCR. Five positive
clones were grown overnight in LB medium containing ampicillin,
and then the plasmids were isolated using a QIAprep Spin
Miniprep Kit (Qiagen) according to the manufacturer’s protocol.
Each vector construct was sequenced to ensure an open reading
frame. Recombinant CL-1 was expressed as a fusion protein with
His-Tag in E. coli BL21 as described above for the recSAP2.
RecCL1 from E. coli was purified under denaturing conditions (8M
Urea) using packed columns (Protino Ni-IDA 150, Macherey &
Nagel) according to the instructions of the manufacturer. The
eluate was passed through PD10 desalting columns (GE
Healthcare) and then was dialyzed against PBS. Purified protein
samples were examined in silver-stained SDS-PAGE gels [21] and
by Western blot [22].
ELISA
FhES-, recSAP2- and ecCL1-ELISAs were carried out essen-
tially as described for Echinococcus antigens [23]. Briefly, sera were
diluted 1:100 and tested using the following antigens (at optimized
coating concentrations): FhES-antigen (10 mg protein per ml);
recSAP2-antigen (0.1 mg protein per ml); recCL1-antigen (0.1 mg
protein per ml). A fourth ELISA included a double-coating with a
mix of 0.1 mg protein of recSAP2 and recCL1 per ml. As a
conjugate, an anti-human-IgG-alkaline phosphatase [ahuIgG-AP]
conjugate (Sigma; 1:1’000 dilution) or a ProteinA-ProteinG-AP-
conjugate [PAG-AP] (Thermo Scientific no. 32391; 1:10’000
dilution) was used. The four Fasciola-antigen-ELISAs validated
here were first calibrated, in order to determine the optimal
threshold (cut-off value) for the discrimination between positive
and negative findings. The individual cut-off value was thus
determined by testing blood donor sera and tumor patients’ sera
and potentially cross-reactive sera (from patients with other
parasitic diseases) as a one group together, thus reaching a
representative average number of the ‘‘negative samples’’
encountered in a routine laboratory. Inter-test and intra-test
variations in test results were calculated as coefficients of variation
for reference negative and positive sera, all tested in triplicate on
each test plate; variation of #15% was recorded, which is
considered acceptable for serodiagnostic assays [2].
Statistical analyses
For statistical analyses, the samples from the 30 patients with
confirmed F. hepatica infection represented the positive status (1),
whereas the 20 healthy individuals, the 121 cancer patients and
the 87 patients infected with potentially cross-reacting or
diagnostically relevant other parasitic infections, all represented
the negative status (0). The comparative evaluation of the four
assays (i.e. FhES-ELISA; recSAP2-ELISA; recCL1-ELISA; re-
cSAP2-recCL1-ELISA) was carried out using this classification.
To quantify the linear numerical correlation between the raw data
measurements of the three assays, Spearman rank correlation
recSAP2- and recCL1- in Human Fasciola-ELISA
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coefficients were derived using all 248 samples. The distribution of
OD405 nm-values for the samples in the three assays was displayed
using dot plots and box plots. In a Receiver-Operator-Character-
istic (ROC) analysis, threshold (cut-off) values for the following
four conditions were derived according to:
(i) Cut-off for the maximum specificity (SP) where the
sensitivity (SE) was still 100%
(ii) Cut-off for the maximum value for Youdens J = SE + Sp 2
1
(iii) Cut-off for the maximum overall accuracy = (true positives
+ true negatives)/n
(iv) Cut-off for the maximum sensitivity at which the specificity
was still 100%
In addition, modified two-graph ROC curves were drawn for
the different assays, and the areas under the ROC curves (AUC)
were statistically compared for significant differences. Descriptive
statistics, plots and ROC analyses were done Microsoft Excel 2010
(www.microsoft.com) and the statistical software package NCCS 8
(www.ncss.com).
Attention to cross-reactivity
The highest potential for a false positive interpretation of test
results relates to sera from patients suffering from other parasitic
diseases. In Table 1, we present the different parasitic diseases and
their rate of cross-reactivity determined in the different ELISA-
types, yielding a relative specificity index linked to cross-reactivity.
To determine the threshold between positive and negative results,
the cut-off value was arbitrarily set at the Youdens J maximum
value, calculated as described above (MedCalc software version
12.7.5.0; http://www.medcalc.org).
List accession numbers
GenBank accession number for the used cDNA-SAP2 stretch:
AF286903.1.
GenBank accession number for the complete cDNA sequence
encoding F. hepatica secreted CL1: U62288.2.
Results
recSAP2 production and analysis
Five batches of recSAP2 and five batches of recCL1 were
both independently produced and analysed by silver staining
(data not shown). As all batches yielded identical purities, they
were pooled to obtain two single working batches, respectively.
These batches were each assessed with known fasciolosis-sera by
Western blot to verify the antigenicity of the two single bands of
expected relative mobilities of Mr 15000 and Mr 26000 for
recSAP2 and recCL1, respectively (data shown for recSAP2
only, Figure 1). Fasciolosis-sera were selected, such as to cover
the whole range of antibody levels measured by the conven-
tional FhES-ELISA. The relationship between ‘‘banding inten-
sity’’ and FhES-ELISA antibody level was relative. Serum a1
has the highest levels in FhES-ELISA (.100 AU, relative
antibody units: The quantification of these ELISA-results,
expressed in relative antibody units [AU], arises from the
routine serology carried out at the Institute of Parasitology in
Bern, and is not further specified in this article), and exhibited
also the strongest staining intensity by Western blot. Sera
nos. a2–a5 yielded medium FhES-ELISA antibody levels (70,
40, 51 and 66 AU), while staining intensity in Western blot
varied considerably and appeared not to be directly linked to
the recSAP2-ELISA findings. Serum a6 was very weak in FhES-
ELISA, and was not detectable by Western blot analysis.
However, the same serum (a6) was, nevertheless, also weakly
positive in recSAP2-ELISA (Figure 1).
Distribution of absorbance values (A405 nm)
The distribution of absorbance values varied considerably
between test positive and negative samples, as to be expected,
but also between different assays (Figure 2), and different optimal
Table 1. Degree of cross-reactivity found with the four antigens assessed by ELISA, and based upon a discrimination between
positive versus negative reaction (Youdens J max), yielding thus a relative specificity index with regard to cross-reactive parasitic
disease sera.
Parasitic disease ntot (FhES-ELISA) npos (recCL1) npos (recCL1-SAP2) npos (recSAP2) npos
neuro-cysticercosis 7 1 1 1 0
cystic echinococosis 5 0 0 0 0
alveolar echinococcosis 5 1 1 1 1
hepatic amoebosis 7 0 0 0 0
visceral leishmaniosis 7 0 3 3 0
malaria (falciparum) 8 0 0 0 0
filariosis/onchocercosis 6 2 0 0 0
strongyloidosis 6 0 0 0 0
ascariosis 10 0 0 0 0
larva migrans (toxocarosis) 10 0 0 0 0
trichinellosis (T. spiralis) 8 0 0 0 0
schistosomosis 8 0 0 0 0
Total 87 4 5 5 1
relative specificity 95% 94% 94% 99%
ntot = total number of sera tested; npos = number of positive sera.
doi:10.1371/journal.pntd.0002860.t001
recSAP2- and recCL1- in Human Fasciola-ELISA
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cut-off values were established for the four tests (see section of
ROC analyses).
ROC analyses
The highest overall accuracy (agreement between references
status and test result) reached was 0.984, while the highest
combined sensitivity and specificity (Youdens J) was 0.905 (Table 2,
Figure 3). The recSAP2-ELISA cut-off 0.084 showed the best
combination of sensitivity (0.867) and specificity (0.989) of the
three recombinant-antigen assays (Table 2). For this assay, the
empirical values for sensitivity, specificity, overall accuracy and
Youdens J, as a function of the cut-off value, were plotted in a
multi-line ROC graph (Figure 4) to illustrate the pattern of these
test characteristics over a range of cut-off values. When comparing
the AUC values of the four tests, test results of the recCL1 assay
were significantly lower than for all other assays (p,0.001), while
results of the FhES assay were significantly higher, even when
compared with the second best assay (recSAP2; p,0.047).
Cross-reactivity
Cross-reactions, as a results of a positive-negative discrimi-
nation based on the cut-off value selected, are presented
according to the different parasitic disease groups investigated
(Table 1). One serum (a case of alveolar echinococcosis)
consistently cross-reacted in all four ELISAs, whereas all other
cross-reactions were individually scattered among individual
ELISAs. The best score in specificity (99%) was achieved by
recSAP2-ELISA, with a single instance of cross-reactivity
(described above).
Diagnostic sensitivity
Using the selected cut-offs, FhES exhibited the best level of
diagnostic sensitivity (93%) (28 positive sera of 30 Fasciola-cases),
followed by recSAP2 (26 of 30 cases; 87%), while the
sensitivities achieved using recCL1 and the combination of
recCL1 and recSAP2 were all below 77% for all elaborated cut-
offs (Table 2).
Figure 1. Western blot analyses of recSAP2-antigen. Arrow indicates the 15 Mr size of the revealed recombinant and affinity-purified protein.
Western blot findings concerning six different sera from fascioliosis patients with different FhES-ELISA-ahuIgG-AP antibody levels (see text).
doi:10.1371/journal.pntd.0002860.g001
recSAP2- and recCL1- in Human Fasciola-ELISA
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Discussion
Coprological diagnosis, based on the identification of F. hepatica
eggs found in stools, duodenal contents or bile analysis is still
commonly employed as a ‘‘gold standard’’ to detect human
fasciolosis. This is the case, despite the consensus that this method
is not entirely reliable [24] for reasons such as: (i) eggs are not
detected until the patent period of infection, when much of the
liver damage has already occurred by the migration of juvenile
flukes in the liver parenchyma, (ii) eggs are released sporadically
from the bile ducts and, hence, stool samples from infected
patients may not necessarily contain eggs [25]. Therefore,
serological techniques play an important complementary role in
the diagnosis of clinical cases of fasciolosis. In the situation of low
endemicity, such as encountered in many countries of Central
Europe, serological methods require not only a good diagnostic
sensitivity, but more importantly also a high specificity. The reason
is that potentially cross- or false-positively reacting sera will be
much more frequently found in routine diagnosis than actual true
cases of fasciolosis. This has to be considered particularly in the
context of a differential diagnosis, predominantly related to any
other hepatic disorders resembling, symptomatically, those of
fasciolosis.
Serodiagnosis of fasciolosis of humans has been successfully
performed by employing several antigens (antigen fractions) of F.
hepatica, where, to date, ES products have become the most
commonly used antigen in-house ELISAs [24]. Nevertheless, the
use of FhES is associated with several problems when used for
routine diagnostic laboratory conditions, including (1) a depen-
dence on the availability of living flukes and (2) representing an
antigen mixture that is subjected to variations due to natural and
artificial conditions (e.g. time between slaughter and cultivation).
Figure 2. Dot plot showing the distribution of A405 nm values (y-axis) for the four antigens/ELISAs and for the four groups of sera
tested (Fh-infection; healthy blood donors; cancer-patients, sera from patients with other parasitoses). The dotted lines indicate the
respective Youndens J max values as shown in Tab. 2 and used as threshold discriminating between positive and negative serology.
doi:10.1371/journal.pntd.0002860.g002
recSAP2- and recCL1- in Human Fasciola-ELISA
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This makes antigen standardization between diagnostic laborato-
ries difficult, whereas a recombinant single component antigen
exhibits a constant composition. With regard to recombinant
antigens, cathepsin L1 (CL1) and saposin-like protein 2 (SAP2)
from F. hepatica are of the most frequently referenced candidates
being used for detecting anti-Fasciola antibodies in different
epidemiological situations [12,15,16,26,27]. For the present study,
we selected both SAP2 and CL1 as key candidates to be
compared, alone or in combination, in the form of bacterially-
expressed recombinant antigens (recSAP2 and recCL1). As a
serological standard, we used a conventionally employed F. hepatica
ES antigen (FhES). In order to improve routine applicability of
any of these tests, we carried out a preliminary study comparing
the efficacy of anti-human-IgG-alkaline phosphatase and a
ProteinA-ProteinG-alkaline phosphates conjugate (PAG-AP) to
detect anti-Fasciola-antibodies (data not shown). We documented a
comparable performance of both conjugates (even slightly
improved for PAG, although statistically not significant). PAG-
AP offers the considerable advantage that it binds also to IgG of
several animal species, including, for example, rabbit IgG. The
availability of sufficient positive control serum for routine
diagnostic application under ISO 17025 accreditation conditions
is one of the big problems in routine diagnostic laboratories, as the
procurement of such serum (in larger quantities) from fasciolosis
patients is difficult or even impossible in countries of low
endemicity. Alternatively, hyperimmune serum from rabbits or
other appropriately immunized animals can assume the role of
positive control reagents, thus considerably facilitating the
establishment of standardized operating procedures (SOPs) of
Fasciola-serology.
The results of the present, comparative study demonstrated
similar performances of the FhES and the recSAP2 antigen with
regard to diagnostic sensitivity and specificity, whereas the assay
using antigen recCL1 did not reach the expected performance.
Our initial working hypothesis had been based on the assumption
that a combination of recSAP1 and recCL1 would increase
diagnostic sensitivity, provided specificity could be maintained.
This hypothesis was justified by an advanced appraisal of previous
publications on the topic. Carnevale et al. [26], who used a
recombinant CL1 containing the proregion of the protein,
reported 100% sensitivity and 100% specificity. In this study,
however, the selection criteria, from both clinical and epidemio-
logical perspectives, have not been described, such that one cannot
elucidate whether 100% sensitivity represents a true diagnostic
sensitivity, as encountered in a routine diagnostic laboratory.
Similarly, Tantrawatpan et al. [28], who used a peptide-based
form of CL1 deduced from F. gigantica, reported 100% sensitivity
and 99.7% specificity. However, in the latter publication, the pre-
selection criteria for the fasciolosis sera were not documented as to
allow an assessment of the actual diagnostic sensitivity. Such tests
should also include sera from acute cases, for which infection had
been proven but eggs could not be detected repeatedly using a
coprological sedimentation technique. For example, sera from
acute cases were not included in the study by O’Neill et al. [16];
these authors reported 100% sensitivity for an ELISA using CL1
expressed in Saccharomyces cerevisiae (yeast) and an anti-IgG4-
detection systems following the testing of sera from 26 cases with
egg-excretion. However, these authors did not evaluate the true
sensitivity by testing sera from cases representing various forms of
infection and disease stages. A relatively recent study on
recombinant CL1 was carried out by Gonzales Santana et al.
[27] upon use of Pichia pastoris for expressing recFhCL1.
Conversely to our study, the antigen demonstrated not only an
excellent diagnostic sensitivity, but also an optimal specificity. The
reason for the difference encountered between these study findings
and our study may be the found by the fact that expression of a
metazoan gene such as cl1 in P. pastoris may much better lead to
carboxylation of the antigen, and thus to an improved formation
of relevant epitopes within this proteinic antigen. We will address
this important feature in our next studies. Another reason why the
diagnostic sensitivity of recCL1 was higher in other studies [16]
may have been the use of a subclass-specific anti-IgG4-conjugate.
Table 2. Selected cutoff values (*) for which the maximized accuracy criterion (diagnostic sensitivity, diagnostic specificity, overall
agreement and combined SE and SP (Youdens J)) was achieved; the table includes also the ROC AUC for the four different Fasciola-
ELISAs.
Test Cutoff Sensitivity Specificity Agreement Youdens J ROC AUC
recCL1 0.020 1.000 0.028 0.167 0.028 0.539
recCL1 0.210 0.233 0.950 0.847 0.183*
recCL1 0.440 0.133 0.994 0.871 0.128
recCL1 0.490 0.067 1.000 0.866 0.067
rCL1rSAP2 0.000 1.000 0.000 0.144 0.000 0.907
rCL1rSAP2 0.210 0.767 0.955 0.928 0.722*
rCL1rSAP2 0.410 0.667 0.994 0.947 0.661
rCL1rSAP2 0.590 0.567 1.000 0.938 0.567
recSAP2 0.007 1.000 0.034 0.172 0.034 0.918
recSAP2 0.084 0.867 0.989 0.971 0.856*
recSAP2 0.084 0.867 0.989 0.971 0.856
recSAP2 0.129 0.800 1.000 0.971 0.800
FhES 0.056 1.000 0.531 0.598 0.531 0.984
FhES 0.252 0.933 0.972 0.967 0.905*
FhES 0.989 0.867 1.000 0.981 0.867
FhES 0.989 0.867 1.000 0.981 0.867
doi:10.1371/journal.pntd.0002860.t002
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The same approach (anti-IgG4-conjugate) was chosen by
Tantrawatpan et al. [28], who furthermore employed a peptide-
based synthetic FhCL1-antigen. Although we know that the
protein A and protein G used in our study, both principally bind to
human IgG4 (http://www.amsbio.com/brochures/Protein-A-
G%20-Affinity-for-IgG-subclasses.pdf), it will be nevertheless
interesting to compare, in future studies, both conjugate types
directly with regard to the diagnostic sensitivity yield.
In our study, bacterially expressed recCL1 exhibited two related
problems, which finally rendered this antigen not useable for our
purpose. First, in comparison to recSAP2, recCL1 displayed
relatively high background reactivity with both, sera from cancer
patients and sera from patients suffering from other parasitoses
(see Figure 2). This translated into a relatively high cut-off level for
the discrimination between seropositivity and seronegativity and,
thus, resulted in a relatively low diagnostic sensitivity. Neverthe-
less, we raised the question whether, among the four recSAP2-
seronegative fasciolosis patients, one or more of them would be
recCL1-positive, thus justifying a possible combination of the two
antigens. However, this was not the case. In this context, it is also
important to mention that the two FhES-negative fasciolosis
patients were also seronegative against the recSAP2 and recCL1
antigens. Consequently, an overall appraisal of the results did not
suggest a routine application of recCL1 antigen for the serodiag-
nosis of human fasciolosis. Nevertheless, as other previous reports
clearly documented a good diagnostic performance of recCL1 if
produced by a different expression system [16] or as a synthetic
polypeptide [28], we will, in future studies, switch from bacterial
expression to the other expression/synthesis systems.
A detailed comparison between the diagnostic operating
characteristics of the recSAP2-ELISA and the other Fasciola-
ELISAs included in our study demonstrated clearly an excellent
performance of recSAP2 in relation to both specificity and cross-
reactivity (specificity 99%, see Tab. 1). Regarding diagnostic
sensitivities, among the 30 fasciolosis patients available for our
study, only one patient with a coprologically confirmed fasciolosis
remained consistently negative in all four tests, including the
recSAP2-ELISA. Due to the lack of clinical data from the
respective patient, the reason for this false-negative result could not
be established. Here, the lack of clinical and radiological evidence
might indicate a chronic infection status with a low infection
intensity, accompanied by a decline or even disappearance of
Figure 3. Empirical ROC curves for the four antigens/ELISAs tested.
doi:10.1371/journal.pntd.0002860.g003
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parasite-specific antibody levels. In this respect, it is possible that
especially the hepatic parenchymal migration stage of juvenile
flukes early during infection induces the strongest immune
response, whereas a few adult worms remaining in the bile ducts
during the chronic phase of infection might not be sufficient to
sustain an antigen stimulus to maintain a detectable serum
antibody level. Overall, sera from four fasciolosis patients were
test-negative in both recombinant antigen-based assays, while
three of them were clearly seropositive in the conventional FhES-
ELISA. However, this slight diagnostic inferiority of recSAP2 as
compared with FhES was largely compensated by other param-
eters that favored SAP2 as a routine serodiagnostic tool,
particularly when applied in a low endemicity area. In such a
situation, the comparatively higher specificity of recSAP2 (99%
versus 95%, see Table 1) might be superior to the comparatively
higher sensitivity of FhES (87% versus 93%). Importantly, in
contrast to FhES, recSAP2 did not exhibit occasional cross-
reactions with sera from neuro-cysticercosis and filariosis patients
(see Table 1). Such cross-reactions might hamper the diagnostic
performance in cases where other clinical data are inconclusive,
and where serology becomes a crucially important diagnostic tool.
In conclusion, we consider the recSAP2-PAG-AP-ELISA as
serological test system for routine diagnosis of human fasciolosis,
particularly if test results are supported by clinical history and the
use of other serological tests controlling for possible cross-reactions
due to antibodies induced by other helminths. In addition, this test
system might serve as an excellent serodiagnostic tool for
epidemiological studies of human fasciolosis, particularly in the
context of outbreaks, or accumulated case numbers, for example,
as observed recently in Switzerland [19]. Our conclusions are in
perfect agreement with a previous report from Figueroa-Santiago
et al. [15], who were the first authors to document the excellent
diagnostic performance of the recSAP2-ELISA.
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Figure 4. Multi-Graph ROC curve showing the empirical value for sensitivity (red), specificity (blue), overall accuracy (green) and
Youdens J (violet) as a function of the cutoff value, exemplified in function of the recSAP2-ELISA selected as best operating ELISA
among the four assays investigated. The blue line indicates the cutoff (0.084) at which the overall test performance turned out to be optimal.
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